Today, a Director at Akorn (AKRX), Terry Allison Rappuhn, bought shares of AKRX for $40.3K.
This recent transaction increases Terry Allison Rappuhn’s holding in the company by 17.18% to a total of $295.3K. This is Rappuhn’s first transaction since reporting a Buy transaction on SPAN back in May 2016
See today’s analyst top recommended stocks >>
Currently, Akorn has an average volume of 1.27M.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $6.50, reflecting a 50.1% upside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health business segments.
